Chad M. Robins's most recent trade in Adaptive Biotechnologies Corp was a trade of 355,000 Common Stock done . Disclosure was reported to the exchange on March 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 355,000 | 2,931,701 (2%) | 0% | 0 | Common Stock | |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 247,117 | 3,061,467 (2%) | 0% | 0 | Common Stock | |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 7.64 per share. | 04 Mar 2025 | 102,218 | 2,959,249 (2%) | 0% | 7.6 | 780,946 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 6.98 per share. | 04 Mar 2025 | 81,206 | 2,850,495 (2%) | 0% | 7.0 | 566,818 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 6.99 per share. | 04 Mar 2025 | 36,145 | 2,814,350 (2%) | 0% | 7.0 | 252,654 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 19 Feb 2025 | 186,080 | 2,762,781 (2%) | 0% | 6.3 | 1,176,026 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 8.46 per share. | 19 Feb 2025 | 186,080 | 2,576,701 (2%) | 0% | 8.5 | 1,574,237 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 186,080 | 99,107 | - | - | Stock Option (right to buy) | |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 19 Feb 2025 | 99,107 | 2,675,808 (2%) | 0% | 6.3 | 626,356 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 8.44 per share. | 19 Feb 2025 | 99,107 | 2,576,701 (2%) | 0% | 8.4 | 836,463 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 99,107 | 0 | - | - | Stock Option (right to buy) | |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 13 Feb 2025 | 211,160 | 2,787,861 (2%) | 0% | 6.3 | 1,334,531 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 8.50 per share. | 13 Feb 2025 | 211,160 | 2,576,701 (2%) | 0% | 8.5 | 1,794,860 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 211,160 | 285,187 | - | - | Stock Option (right to buy) | |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 13 Feb 2025 | 158,921 | 2,735,622 (2%) | 0% | 6.3 | 1,004,381 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 8.46 per share. | 13 Feb 2025 | 158,921 | 2,576,701 (2%) | 0% | 8.5 | 1,344,472 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 158,921 | 496,347 | - | - | Stock Option (right to buy) | |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 13 Feb 2025 | 100,287 | 2,676,988 (2%) | 0% | 6.3 | 633,814 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 8.44 per share. | 13 Feb 2025 | 100,287 | 2,576,701 (2%) | 0% | 8.4 | 846,422 | Common Stock |
| Adaptive Biotechnologies Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 100,287 | 655,268 | - | - | Stock Option (right to buy) |